IL1B and Venous thrombosis: Considering the positive results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) showing that IL-1β blockade significantly reduced the number of CV events,42 as well as CV mortality in patients that responded with reduced hsCRP,43,44 DCA and/or other PDK blockers emerge as an attractive alternative to inhibit the deleterious effects of this pathway on CVD.